Bibliography: Schizophrenia: Advances in Understanding and Treatment

Bechtold J, Hipwell A, Lewis DA, et al.: Concurrent and sustained cumulative effects of adolescent marijuana use on subclinical psychotic symptoms. Am J Psychiatry (Epub ahead of print, May 3, 2016)Google Scholar

Clementz BA, Sweeney JA, Hamm JP, et al.: Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry 2016; 173:373–384Crossref, Google Scholar

Cristóbal-Narváez P, Sheinbaum T, Ballespí S, et al: Impact of adverse childhood experiences on psychotic-like symptoms and stress reactivity in daily life in nonclinical young adults. PLoS One 2016; 11:e0153557Google Scholar

Heilbronner U, Samara M, Leucht S, et al.: The longitudinal course of schizophrenia across the lifespan: clinical, cognitive, and neurobiological aspects. Harv Rev Psychiatry 2016; 24:118–128Crossref, Google Scholar

Kane JM, Robinson DG, Schooler NR, et al.: Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. Am J Psychiatry 2016; 173:362–372Crossref, Google Scholar

McEvoy J, Citrome L: Brexpiprazole for the treatment of schizophrenia: a review of this novel serotonin-dopamine activity modulator. Clin Schizophr Relat Psychoses 2016; 9:177–186Crossref, Google Scholar

Tek C, Kucukgoncu S, Guloksuz S, et al: Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry 2016; 10:193–202Google Scholar

Connery HS: Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry 2015; 23:63–75Crossref, Google Scholar

Farrell MS, Werge T, Sklar P, et al.: Evaluating historical candidate genes for schizophrenia. Mol Psychiatry 2015; 20:555–562Crossref, Google Scholar

Green MF, Horan WP, Lee J: Social cognition in schizophrenia. Nat Rev Neurosci 2015; 16:620–631Crossref, Google Scholar

Haring L, Koido K, Vasar V, et al.: Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index. Schizophr Res 2015; 169:22–29Crossref, Google Scholar

Kane JM, Zukin S, Wang Y, et al.: Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol 2015; 35:367–373Google Scholar

Laurens KR, Luo L, Matheson SL, et al.: Common or distinct pathways to psychosis? A systematic review of evidence from prospective studies for developmental risk factors and antecedents of the schizophrenia spectrum disorders and affective psychoses. BMC Psychiatry 2015; 15:205Crossref, Google Scholar

Lee J, Takeuchi H, Fervaha G, et al: Subtyping schizophrenia by treatment response: antipsychotic development and the central role of positive symptoms. Can J Psychiatry 2015; 60:515–522Google Scholar

Leucht S, Winter-van Rossum I, Heres S, et al: The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull 2015; 41:549–558Google Scholar

McFarlane WR, Levin B, Travis L, et al.: Clinical and functional outcomes after 2 years in the Early Detection and Intervention for the Prevention of Psychosis multisite effectiveness trial. Schizophr Bull 2015; 41:30–43Crossref, Google Scholar

Mueser KT, Penn DL, Addington J, et al.: The NAVIGATE program for first-episode psychosis: rationale, overview, and description of psychosocial components. Psychiatr Serv 2015; 66:680–690Crossref, Google Scholar

Pearlson GD: Etiologic, phenomenologic, and endophenotypic overlap of schizophrenia and bipolar disorder. Annu Rev Clin Psychol 2015; 11:251–281Crossref, Google Scholar

Siu CO, Harvey PD, Agid O, et al.: Insight and subjective measures of quality of life in chronic schizophrenia. Schizophr Res Cogn 2015; 2:127–132Crossref, Google Scholar

Bentall RP, de Sousa P, Varese F, et al.: From adversity to psychosis: pathways and mechanisms from specific adversities to specific symptoms. Soc Psychiatry Psychiatr Epidemiol 2014; 49:1011–1022Crossref, Google Scholar

Correll CU, Kane JM: Schizophrenia: mechanism of action of current and novel treatments. J Clin Psychiatry 2014; 75:347–348Crossref, Google Scholar

Keshavan MS, Vinogradov S, Rumsey J, et al.: Cognitive training in mental disorders: update and future directions. Am J Psychiatry 2014; 171:510–522Crossref, Google Scholar

Schizophrenia Working Group of the Psychiatric Genomics Consortium: Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511:421–427Crossref, Google Scholar

Stan AD, Tamminga CA: New options for the treatment of schizophrenia: a clinical review of the three most recent antipsychotic drugs. Focus 2014; 12:127–135Link, Google Scholar

Andreasen NC, Liu D, Ziebell S, et al.: Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013; 170:609–615Crossref, Google Scholar

Driver DI, Gogtay N, Rapoport JL: Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. Child Adolesc Psychiatr Clin N Am 2013; 22:539–555Crossref, Google Scholar

Greenwood TA, Swerdlow NR, Gur RE, et al.: Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry 2013; 170:521–532Crossref, Google Scholar

Heckers S, Barch DM, Bustillo J, et al: Structure of the psychotic disorders classification in DSM-5. Schizophr Res 2013; 150:11–14Google Scholar

Kranzler HN, Cohen SD: Psychopharmacologic treatment of psychosis in children and adolescents: efficacy and management. Child Adolesc Psychiatr Clin N Am 2013; 22:727–744Crossref, Google Scholar

Leucht S, Cipriani A, Spineli L, et al.: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382:951–962 (Reprinted in Focus 2014; 12:192–204)Crossref, Google Scholar

McClellan J, Stock S: Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2013; 52:976–990. http://www.jaacap.com/article/S0890-8567(13)00112-3/pdfCrossref, Google Scholar

Sikich L: Diagnosis and evaluation of hallucinations and other psychotic symptoms in children and adolescents. Child Adolesc Psychiatr Clin N Am 2013; 22:655–673Crossref, Google Scholar

Bechdolf A, Wagner M, Ruhrmann S, et al.: Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry 2012; 200:22–29Crossref, Google Scholar

Cerimele JM, Durango A: Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies. J Clin Psychiatry 2012; 73:e1039–e1047Crossref, Google Scholar

Clemmensen L, Vernal DL, Steinhausen HC: A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry 2012; 12:150Crossref, Google Scholar

Kingdon DG, Turkington D: Cognitive-Behavioral Therapy of Schizophrenia. New York, Guilford, 1994Google Scholar

Lencer R, Harris MSH, Weiden PJ, et al.: When Psychopharmacology Is Not Enough: Using Cognitive Behavioral Therapy Techniques for Persons With Persistent Psychosis. Boston, Hogrefe, 2011Google Scholar

Stone JM: Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? Ther Adv Psychopharmacol 2011; 1:5–18Crossref, Google Scholar